metastatic non-small cell lung cancer

FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC
FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC
Pharmaceutical Business Review
Bristol-Myers Squibb
Opdvio
Yervoy
metastatic non-small cell lung cancer
Flag link:
FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC
FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC
Pharmaceutical Business Review
Genentech
Roche
Tecentriq
FDA
metastatic non-small cell lung cancer
Flag link:
Roche’s TIGIT drug shows promise in untreated lung cancer
Roche’s TIGIT drug shows promise in untreated lung cancer
Pharmaforum
Roche
ASCO 2020
tiragolumab
Tecentriq
metastatic non-small cell lung cancer
Flag link:
Takeda gets FDA breakthrough therapy status for mobocertinib to treat certain type of lung cancer
Takeda gets FDA breakthrough therapy status for mobocertinib to treat certain type of lung cancer
Pharmaceutical Business Review
Takeda
FDA
mobocertinib
metastatic non-small cell lung cancer
Flag link:
J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation
J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation
BioSpace
Janssen
JNJ
FDA
JNJ-6372
breakthrough therapy
metastatic non-small cell lung cancer
Flag link:
Janssen gets FDA breakthrough therapy status for JNJ-6372 to treat metastatic NSCLC
Janssen gets FDA breakthrough therapy status for JNJ-6372 to treat metastatic NSCLC
Pharmaceutical Business Review
Janssen
JNJ
FDA
JNJ-6372
metastatic non-small cell lung cancer
Flag link:
Sandoz launches oncology generic gefitinib in 13 EU countries
Sandoz launches oncology generic gefitinib in 13 EU countries
Pharmaceutical Business Review
Sandoz
Novartis
generics
gefitinib
metastatic non-small cell lung cancer
Flag link:
Lilly's combo treatment meets main goal in lung cancer late-stage study
Lilly's combo treatment meets main goal in lung cancer late-stage study
Yahoo/Reuters
Eli Lilly
Cyramza
clinical trials
metastatic non-small cell lung cancer
Roche
erlotinib
Flag link:
Merck's Keytruda faces delay in first-line approval decision
Merck's Keytruda faces delay in first-line approval decision
Biopharma Dive
FDA
Keytruda
Merck
metastatic non-small cell lung cancer
Flag link:
FDA Grants Pfizer's Xalkori Breakthrough Therapy Status for Two New Indications
FDA Grants Pfizer's Xalkori Breakthrough Therapy Status for Two New Indications
CP Wire
Pfizer
Xalkori
metastatic non-small cell lung cancer
FDA
breakthrough therapies
anaplastic large-cell lymphoma
Flag link:
EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer
EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer
CP Wire
Bristol-Myers Squibb
Opdivo
Yervoy
metastatic non-small cell lung cancer
EMA
Europe
Flag link:
Merck's stock surges after positive Keytruda trial results
Merck's stock surges after positive Keytruda trial results
Marketwatch
Merck
Keytruda
clinical trials
metastatic non-small cell lung cancer
Flag link:
Immunotherapy Combination Trial in Metastatic Lung Cancer Shows Promise of Success
Immunotherapy Combination Trial in Metastatic Lung Cancer Shows Promise of Success
CP Wire
metastatic non-small cell lung cancer
Altor Bioscience
ALT-803
Opdivo
Bristol-Myers Squibb
Flag link:
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
Motley Fool
cancer
oncology
Pfizer
Ibrance
breast cancer
Xtandi
prostate cancer
Bavencio
bladder cancer
Merkel cell carcinoma
lorlatinib
metastatic non-small cell lung cancer
talazoparib
metastatic breast cancer
Flag link:
Pfizer wins a “breakthrough” title for ALK/ROS1 contender lorlatinib after hustling into PhIII
Pfizer wins a “breakthrough” title for ALK/ROS1 contender lorlatinib after hustling into PhIII
Endpoints
Pfizer
breakthrough status
lorlatinib
metastatic non-small cell lung cancer
Flag link:
Novartis' Lung Cancer Drug Combo Gets EU Nod
Novartis' Lung Cancer Drug Combo Gets EU Nod
Investopedia
Novartis
Europe
metastatic non-small cell lung cancer
Tafinlar
Mekinist
Flag link:
Merck's Keytruda Approved for Lung Cancer in EU
Merck's Keytruda Approved for Lung Cancer in EU
Investopedia
Merck
Keytruda
Europe
metastatic non-small cell lung cancer
Flag link:
KEYTRUDA® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
KEYTRUDA® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Yahoo
Keytruda
Merck
metastatic non-small cell lung cancer
Flag link:
FDA approves Merck's lung cancer drug as first-line treatment
FDA approves Merck's lung cancer drug as first-line treatment
Yahoo/Reuters
FDA
Merck
Keytruda
metastatic non-small cell lung cancer
Flag link:
Bristol-Myers’s Drug Combination Boosts Lung Cancer Benefit
Bristol-Myers’s Drug Combination Boosts Lung Cancer Benefit
Bloomberg
Bristol-Myers Squibb
Yervoy
Opdivo
metastatic non-small cell lung cancer
Flag link:

Pages